Back to Search
Start Over
Towards a Precision Medicine Approach and In Situ Vaccination against Prostate Cancer by PSMA-Retargeted oHSV
- Source :
- Viruses, Volume 13, Issue 10, Viruses, Vol 13, Iss 2085, p 2085 (2021)
- Publication Year :
- 2021
- Publisher :
- MDPI AG, 2021.
-
Abstract
- Prostate specific membrane antigen (PSMA) is a specific high frequency cell surface marker of prostate cancers. Theranostic approaches targeting PSMA show no major adverse effects and rule out off-tumor toxicity. A PSMA-retargeted oHSV (R-405) was generated which both infected and was cytotoxic exclusively for PSMA-positive cells, including human prostate cancer LNCaP and 22Rv1 cells, and spared PSMA-negative cells. R-405 in vivo efficacy against LLC1-PSMA and Renca-PSMA tumors consisted of inhibiting primary tumor growth, establishing long-term T immune response, immune heating of the microenvironment, de-repression of the anti-tumor immune phenotype, and sensitization to checkpoint blockade. The in situ vaccination protected from distant challenge tumors, both PSMA-positive and PSMA-negative, implying that it was addressed also to LLC1 tumor antigens. PSMA-retargeted oHSVs are a precision medicine tool worth being additionally investigated in the immunotherapeutic and in situ vaccination landscape against prostate cancers.
- Subjects :
- Male
medicine.medical_treatment
Immune checkpoint inhibitor
urologic and male genital diseases
immune checkpoint inhibitors
Prostate cancer
0302 clinical medicine
Prostate
Tumor Microenvironment
Precision Medicine
In Situ Hybridization
Oncolytic Virotherapy
0303 health sciences
oncolytic herpes simplex virus
prostate cancer
Primary tumor
QR1-502
3. Good health
Oncolytic Viruses
Infectious Diseases
medicine.anatomical_structure
030220 oncology & carcinogenesis
Kallikreins
immunotherapy
Oncolytic herpes simplex viru
Antineoplastic Agents
Microbiology
Article
03 medical and health sciences
Immune system
Antigen
Cell Line, Tumor
Virology
LNCaP
PSMA
medicine
Humans
oncolytic virus
retargeting
030304 developmental biology
business.industry
Oncolytic viru
Prostatic Neoplasms
Cancer
Immunotherapy
Prostate-Specific Antigen
vaccination
medicine.disease
in situ vaccine
Cancer research
business
Biomarkers
Subjects
Details
- ISSN :
- 19994915
- Volume :
- 13
- Database :
- OpenAIRE
- Journal :
- Viruses
- Accession number :
- edsair.doi.dedup.....2990f9ea8df03d5c535aa1cadc9514d1